Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 12/20 | 0.59 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.48 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.45 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22866465 | 0.91 | NT5E (0.64) | NT5EDNPH1NR2F2P2RX3P2RX2 | |
| SCHEMBL22866534 | 0.90 | NT5E (0.57) | NT5EDNPH1NR2F2P2RX3P2RX2 | |
| SCHEMBL13467468 | 0.84 | NPC1 (0.48) | NR2F2NPC1RAB9ASMN1; SMN2SLC29A1 | |
| SCHEMBL13467417 | 0.83 | NR2F2 (0.57) | NR2F2NPC1RAB9ASMN1; SMN2SLC29A1 | |
| SCHEMBL30563038 | 0.82 | NT5E (0.85) | NT5EDNPH1P2RX3P2RX2SLC29A1 | |
| SCHEMBL19100967 | 0.82 | NT5E (0.85) | NT5EDNPH1P2RX3P2RX2SLC29A1 | |
| SCHEMBL22843551 | 0.81 | NT5E (0.64) | NT5EDNPH1P2RX3P2RX2 | |
| SCHEMBL23922247 | 0.79 | ENPP1 (0.65) | NT5EP2RX3 | |
| SCHEMBL22524082 | 0.78 | ADORA3 (0.47) | NT5EDNPH1NR2F2P2RX3P2RX2 | |
| SCHEMBL20324865 | 0.77 | P2RY1 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001603-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| US-20210002322-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001603-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | NT5E 3/4885DNPH1 285/4885NR2F2 3245/4885 |
| US-20210002322-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | NT5E 3/4885DNPH1 256/4885NR2F2 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.